Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) was the target of a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 3,141 shares. Based on an average daily volume of 193,851 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are sold short.
Bioxytran Stock Performance
Shares of OTCMKTS:BIXT opened at $0.02 on Wednesday. The firm has a 50 day simple moving average of $0.02 and a 200 day simple moving average of $0.03. Bioxytran has a 52 week low of $0.02 and a 52 week high of $0.09. The company has a market cap of $2.57 million, a PE ratio of -0.75 and a beta of 2.32.
Bioxytran (OTCMKTS:BIXT – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.01) earnings per share (EPS) for the quarter.
About Bioxytran
BioXyTran, Inc is a biotechnology company focused on developing nanotechnology-based therapeutic products. Its research has centered on methods for delivering oxygen and other therapeutic agents through the bloodstream, with the goal of addressing conditions associated with inadequate blood flow and oxygen deprivation.
The company’s lead development program has been identified as BXT-25, an oxygen-delivery product intended for potential use in ischemic conditions, including acute ischemic stroke.
See Also
- Five stocks we like better than Bioxytran
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
